RxDoctor Payments Data

Eric Liu, MD

Internal Medicine · San Diego, CANPI 1609865377

Payments from drug & device makers

$3,242in general payments, 2019–2025

Across 90 payments — averaging $36.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$1K
  • Histosonics, Inc.$667
  • AstraZeneca$235
  • Amgen$230
  • GSK$214
  • AbbVie$113
  • plus $737 from 19 others

What the payments were for

  • Travel & lodging$1,64751%
  • Food & beverage$1,58949%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,242 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$175,680
Medicare patients
433
Services billed
2,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$72,997
EliquisApixaban29$38,919
RybelsusSemaglutide13$25,533
OzempicSemaglutide19$21,413
Breo ElliptaFluticasone/Vilanterol20$12,315
XareltoRivaroxaban15$11,544
Rosuvastatin Calcium319$3,887
Atorvastatin Calcium364$3,513
Losartan Potassium271$3,287
Testosterone15$3,206
SynthroidLevothyroxine Sodium48$2,988
Azelastine Hcl84$2,737
Ipratropium Bromide42$2,421
Levothyroxine Sodium269$2,368
Amlodipine Besylate318$2,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$32$72,99758 claims
Novo NordiskRybelsus, Ozempic$111$46,94632 claims
PfizerEliquis$92$38,91929 claims
GSKBreo Ellipta$214$12,31520 claims
AbbVieSynthroid$113$2,98848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →